Insulin-Like Growth Factor II (IGF-II) and the IGF-II/ Mannose-6-Phosphate Receptor: The Myth Continues
W. Kiess, Yu‐Shih Yang, Ulrike Kessler, Andreas Hoeflich
Abstract
W. Kiess, Yu‐Shih Yang, Ulrike Kessler, Andreas Hoeflich
Abstract
Insulin-like growth factor II (IGF-II) is a polypeptide hormone with structural and functional homology with IGF-I and pro-insulin. It is now thought that IGF-II acts as a growth factor during fetal life and development. In rats, IGF-II levels in the circulation are high in the fetus and decline rapidly after birth. IGF-II mRNA expression in many tissues including the liver and the choroids plexus is also high during fetal life and low thereafter. Targeted disruption of the IGF-II gene in mice leads to a deficiency in their growth. Alternatively, it has been proposed that IGF-II could act as a growth and differentiation factor in the central nervous system. Administration of IGF-II into the central nervous system in rats leads to increased food intake and altered feeding behaviour. In muscle cells and in colon epithelial cells, IGF-II might also serve as an important regulator of differentiation, A key role for IGF-II as a paracrine or autocrine growth factor in certain tumours has been proposed. The IGFs exert their effects by binding to high-affinity membrane receptors that are expressed in many cells and tissues. The IGF-I receptor, which binds IGF-I with the highest affinity and which is very similar to the insulin receptor, is thought to mediate most, if not all, of the IGF-induced biological functions. The IGF-II/ mannose-6-phosphate (M6P) receptor is a bifunctional glycoprotein with no homology to the insulin receptor. This receptor binds IGF-II and lysosomal enzymes bearing the M6P recognition marker at distinct binding sites. The receptor serves to target lysosomal enzymes to lysosomes and thus plays a key role in the degradative system of the cell. The IGF-II and the IGF-II/M6P receptor genes are parentally imprinted in the mouse and in humans; while IGF-II seems to be paternally imprinted, the receptor gene is maternally imprinted. Relaxation or loss of imprinting has recently been recognized as a putative epigenetic mutational mechanism in carcinogenesis. It is now clear that both IGF-II and the IGF-II/M6P receptor are important regulators of growth and development in fetal life, during oncogenesis and possibly during differentiation and tissue remodelling.
OpenAlex reports 53 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Insulin-like growth factor II (IGF-II) is a polypeptide hormone with structural and functional homology with IGF-I and pro-insulin. It is now thought that IGF-II acts as a growth factor during fetal life and development. In rats, IGF-II levels in the circulation are high in the fetus and decline rapidly after birth. IGF-II mRNA expression in many tissues including the liver and the choroids plexus is also high during fetal life and low thereafter. Targeted disruption of the IGF-II gene in mice leads to a deficiency in their growth. Alternatively, it has been proposed that IGF-II could act as a growth and differentiation factor in the central nervous system. Administration of IGF-II into the central nervous system in rats leads to increased food intake and altered feeding behaviour. In muscle cells and in colon epithelial cells, IGF-II might also serve as an important regulator of differentiation, A key role for IGF-II as a paracrine or autocrine growth factor in certain tumours has been proposed. The IGFs exert their effects by binding to high-affinity membrane receptors that are expressed in many cells and tissues. The IGF-I receptor, which binds IGF-I with the highest affinity and which is very similar to the insulin receptor, is thought to mediate most, if not all, of the IGF-induced biological functions. The IGF-II/ mannose-6-phosphate (M6P) receptor is a bifunctional glycoprotein with no homology to the insulin receptor. This receptor binds IGF-II and lysosomal enzymes bearing the M6P recognition marker at distinct binding sites. The receptor serves to target lysosomal enzymes to lysosomes and thus plays a key role in the degradative system of the cell. The IGF-II and the IGF-II/M6P receptor genes are parentally imprinted in the mouse and in humans; while IGF-II seems to be paternally imprinted, the receptor gene is maternally imprinted. Relaxation or loss of imprinting has recently been recognized as a putative epigenetic mutational mechanism in carcinogenesis. It is now clear that both IGF-II and the IGF-II/M6P receptor are important regulators of growth and development in fetal life, during oncogenesis and possibly during differentiation and tissue remodelling.
Key concepts: Endocrinology, Autocrine signalling, Paracrine signalling, Insulin-like growth factor 2, Internal medicine, Biology, Growth factor, Insulin-like growth factor